Back To TOP

We Focus on Access so
You Can Focus on Health

Connecting you to PERJETA® (pertuzumab).
Welcome to PERJETA Access Solutions.

I am a
Learn More About
PERJETA
  • LEARN about treatment with PERJETA
  • LEARN HOW the Genentech BioOncology Co-pay Card can help with the out-of-pocket costs for PERJETA
  • Form Patient Authorization and Notice of Release of Information (Current Version)

What does PERJETA treat?

PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel (chemotherapy) in people with HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

Important Safety Information

  • Most Serious Side Effect: Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects

- If you think you may be pregnant, you should contact your healthcare provider immediately

- If you are exposed to PERJETA during pregnancy, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720

  • Other possible serious side effects of PERJETA therapy include:

- Heart problems

- Infusion-related reactions

- Severe allergic reactions (hypersensitivity reactions/anaphylaxis)

  • PERJETA has been shown to work only in people with HER2-positive breast cancer
  • The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) are:

- Diarrhea

- Hair loss

- Low levels of white blood cells with or without a fever

- Nausea

- Feeling tired

- Rash

- Damage to the nerves (numbness, tingling, pain in hands/feet)

You are encouraged to report side effects to Genentech or the FDA. You may report side effects to the FDA at 1-800-FDA­‐1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see PERJETA full Prescribing Information including Most Serious Side Effect for additional Important Safety Information.